Bleximenib dose optimization from a Phase I trial in patients with R/R acute leukemia скачать в хорошем качестве

Bleximenib dose optimization from a Phase I trial in patients with R/R acute leukemia

Emma Searle, MBChB, MA, MRCP, FRCPath, PhD, The Christie NHS Foundation Trust, Manchester, UK, comments on the results of a Phase I study (NCT04811560) of bleximenib, a novel menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemias with a KMT2A rearrangement or NPM1 mutation. Dr Searle presents the findings on the optimal dose of bleximenib, and mentions side effects that were seen, such as differentiation syndrome. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.